We can’t show the full text here under this license. Use the link below to read it at the source.
Efficacy and hypoglycaemia outcomes with once‐weekly insulin icodec versus once‐daily basal insulin in type 2 diabetes according to baseline glucagon‐like peptide‐1 receptor agonist and sodium‐glucose co‐transporter‐2 inhibitor use: A post hoc analysis of ONWARDS 1–5
Blood sugar control and low blood sugar risk with once-weekly insulin icodec versus daily basal insulin in type 2 diabetes, considering use of common diabetes pills
AI simplified
Abstract
21.3% of participants in ONWARDS 1-5 were treated with a GLP-1 receptor agonist.
- 36.9% of participants were treated with a sodium-glucose co-transporter-2 inhibitor.
- Baseline characteristics were similar across treatment groups, regardless of GLP-1RA or SGLT2i use.
- No statistically significant treatment interactions were observed for changes in glycated hemoglobin or body weight based on GLP-1RA or SGLT2i use.
- Weekly basal insulin doses did not show significant differences related to GLP-1RA or SGLT2i use, except in one trial.
- Rates of clinically significant or severe were generally low, averaging less than one episode per patient-year of exposure.
AI simplified
Key numbers
801 of 3765
Participants treated with GLP-1RAs
Percentage of participants in ONWARDS 1-5 treated with GLP-1RAs at screening.
1388 of 3765
Participants treated with SGLT2is
Percentage of participants in ONWARDS 1-5 treated with SGLT2is at screening.
<1 episode/PYE
rate
Rate of clinically significant or severe across ONWARDS 1, 2, 3, and 5.